Home / Market News / $MCRB

$MCRB news and market catalysts

The 4 most recent market catalysts affecting $MCRB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

4 catalysts 1 high impact 2 bullish 0 bearish Biotechnology
Nov 3, 2026 Corporate Catalyst Neutral Impact 75
Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine
Seres Therapeutics (MCRB) announced the publication of its SER-155 Phase 1b clinical trial results in Nature Medicine. This is a significant event as publication in a prestigious j…
Oct 15, 2026 Corporate Catalyst Bullish Impact 55
Seres Therapeutics To Present Preclinical Data Supporting Development Of SER-428, Investigational Oral Liquid LBP To Reduce Risk Of Bloodstream Infections In Critically Ill Patients, At IDWeek 2026
Seres Therapeutics (MCRB) is announcing an upcoming presentation of preclinical data for SER-428, an investigational oral liquid LBP. This matters because it highlights progress in…
Aug 13, 2026 Corporate Catalyst Neutral Impact 65
Seres Therapeutics Files Prospectus for Up To $300M Offering Of Common Stock, Preferred Stock, Debt, Warrants And Units
Seres Therapeutics has filed a universal shelf registration statement for up to $300 million in various securities. This is a common corporate finance move that provides the compan…
Aug 5, 2026 Corporate Catalyst Bullish Impact 95
Seres Therapeutics Q2 EPS $0.47 Beats $(2.19) Estimate, Sales $736.000K Beat $179.000K Estimate
Seres Therapeutics (MCRB) reported a substantial beat on both its Q2 EPS and sales estimates. The company posted a profit of $0.47 per share, a significant turnaround from an estim…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.